Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

A One Health trial design to accelerate Lassa fever vaccines

Nature Medicine volume 32, pages 25–27 (2026)Cite this article

Subjects

We propose an interdisciplinary framework to address the considerable challenges that are restricting the development of vaccines for zoonotic diseases with epidemic potential.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The proposed OHTD framework.

References

  1. World Health Organization. https://go.nature.com/3IUuBi2 (2024).

  2. Gouglas, D. et al. Lancet Glob. Health 6, e1386–e1396 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  3. Warimwe, G. M. et al. Nat. Rev. Immunol. 21, 815–822 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Smith, D. R. M. et al. Nat. Med. 30, 3568–3577 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. World Health Organization. https://go.nature.com/4pRHM3Q (2017).

  6. Penfold, S. et al. PLoS ONE 18, e0283643 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Mariën, J. et al. J. Infect. Dis. https://doi.org/10.1093/infdis/jiaf308 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Kenmoe, S. et al. PLoS Negl. Trop. Dis. 14, e0008589 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Andersen, K. G. et al. Cell 162, 738–750 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Hoffmann, C. et al. Nat. Commun. 15, 9319 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Redding, D. W. et al. Nat. Commun. 12, 5759 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Latkin, C. A. et al. Addict. Behav. 73, 133–136 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  13. Moore, S. M. et al. PLoS Negl. Trop. Dis. 19, e0012751 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Qian, Y. G., Jombart, T. & Edmunds, W. J. Vaccine X 14, 100321 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  15. Capps, B. & Lederman, Z. J. Agric. Environ. Ethics 28, 1011–1032 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Anthropology, The Pennsylvania State University, University Park, PA, USA

    David Simons & Sagan Friant

  2. Center for Infectious Disease Dynamics, The Pennsylvania State University, University Park, PA, USA

    David Simons & Sagan Friant

  3. Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK

    Deborah Watson-Jones & Daniela Manno

  4. Mwanza Intervention Trials Unit, National Institute for Medical Research, Mwanza, Tanzania

    Deborah Watson-Jones

Authors
  1. David Simons
    View author publications

    Search author on:PubMed Google Scholar

  2. Deborah Watson-Jones
    View author publications

    Search author on:PubMed Google Scholar

  3. Daniela Manno
    View author publications

    Search author on:PubMed Google Scholar

  4. Sagan Friant
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to David Simons.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Simons, D., Watson-Jones, D., Manno, D. et al. A One Health trial design to accelerate Lassa fever vaccines. Nat Med 32, 25–27 (2026). https://doi.org/10.1038/s41591-025-04018-6

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41591-025-04018-6

Search

Advanced search

Quick links

Nature Briefing Microbiology

Sign up for the Nature Briefing: Microbiology newsletter — what matters in microbiology research, free to your inbox weekly.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing: Microbiology